Market capitalization | $290.00k |
Enterprise Value | $-2.15m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | 0.12 |
P/B ratio (TTM) P/B ratio | 0.32 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-17.07m |
Free Cash Flow (TTM) Free Cash Flow | $-17.61m |
Cash position | $2.44m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Neximmune Inc:
1 Analyst has issued a forecast Neximmune Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.68 -0.68 |
56%
56%
|
|
EBITDA | -16 -16 |
66%
66%
|
EBIT (Operating Income) EBIT | -17 -17 |
65%
65%
|
Net Profit | -21 -21 |
58%
58%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Craig Jalbert |
Employees | 6 |
Founded | 2011 |
Website | www.neximmune.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.